Treatment with Adeno-associated viruses (AAV) encoding VEGF-C consistently induced robust and sustained dural lymphatic vessel (dLV) expansion regardless of the injection route (i.c.v. or i.c.m. delivery) across two AD mouse models: APdE9 (analyzed at 9 months to assess early pathology and at 15 months to test effects on established amyloid plaques) and 5xFAD (analyzed at 4.5 months to confirm findings in an aggressive AD model) mice (Antila et al. 2024). The gene discussed is VEGFC; the disease is Alzheimer disease.